腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症临床疗效分析(附425例报告)

Clinical efficacy of laparoscopic splenectomy combined with pericardial devascularization in the treatment of cirrhotic portal hypertension: a report of 425 cases

  • 摘要: 目的:探讨腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症的临床疗效。
    方法:采用回顾性描述性究方法。收集2012年2月至2018年12月扬州大学附属苏北人民医院收治的425例行腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症患者的临床病理资料;男289例,女136例;年龄为(53±11)岁,年龄范围为21~79岁。根据手术时间,将425例患者分为3个时期:早期(2012年2月至2014年3月)100例、技术成熟期(2014年4月至2016年8月)156例、技术创新期(2016年 9月至2018年12月)169例。早期、技术成熟期患者行腹腔镜脾切除联合贲门周围血管离断术,技术创新期患者行保留迷走神经的腹腔镜脾切除联合贲门周围血管离断术。观察指标:(1)手术情况。(2)术后情况。(3)随访情况。采用门诊方式对患者进行随访,了解患者上消化道再出血、胃潴留、腹泻发生情况。根据随访患者门诊胃镜检查结果行内镜下套扎术序贯治疗。随访时间截至2019年3月。正态分布的计量资料以±s表示,多组间比较采用方差分析,两两比较采用t检验;偏态分布的计量资料以M(范围)表示,多组间比较采用Kruskal-Wallis秩和检验,两两比较采用秩和检验;计数资料以绝对数和(或)百分率表示,组间比较采用x2检验或Fisher确切概率法。
    结果:(1)手术情况:早期患者手术时间,术中出血量,术中输血例数,中转开腹例数,急诊止血例数分别为(187±46)min,150 mL(50~1 300 mL),2例,2例,1例。技术成熟期和技术创新期患者上述指标分别为(164±22)min,50 mL(30~100 mL),1例,1例,1例和(150±18)min, 50 mL(10~300 mL),0,0,0。3期患者手术时间、术中出血量比较,差异均有统计学意义(F=55.482, x2=94.620,P<0.05)。3期患者术中输血、中转开腹、急诊止血例数比较,差异均无统计学意义(P>0.05)。(2)术后情况:425例患者无围术期死亡,术后常规口服阿司匹林肠溶片预防血栓。早期患者术后住院时间,术后第7天门静脉血栓例数,胰液漏例数,肺部感染例数,腹腔感染例数分别为(11.0±2.9)d,46例, 2例,1例,0。技术成熟期和技术创新期患者上述指标分别为(9.9±1.7)d,81例,3例,0,0和(8.8±1.3)d,83例,2例,1例,1例。3期患者术后住院时间比较,差异有统计学意义(F=39.836,P<0.05)。技术成熟期患者术后住院时间与早期比较,差异有统计学意义(t=3.329,P<0.05);技术创新期患者术后住院时间与技术成熟期比较,差异有统计学意义(t=6.502,P<0.05)。3期患者术后第7天门静脉血栓例数比较,差异无统计学意义(x2=0.865,P>0.05)。3期患者胰液漏、肺部感染、腹腔感染例数比较,差异均无统计学意义(P>0.05)。术后第7天门静脉血栓患者住院和随访期间采用口服阿司匹林肠溶片或华法林治疗。胰液漏、肺部感染和腹腔感染患者均经保守治疗后康复出院。(3)随访情况:425例患者均获得术后随访,随访时间为1~72个月,中位随访时间为36个月。425例患者随访期间,261例行内镜下套扎术序贯治疗(技术成熟期133例、技术创新期128例)。261例行内镜下套扎术序贯治疗和164例未行内镜下套扎术序贯治疗患者上消化道再出血发生率分别为3.83%(10/261)和17.68%(29/164),两者比较,差异有统计学意义(x2=23.185,P<0.05)。133例行内镜下套扎术序贯治疗技术成熟期患者胃潴留、腹泻发生率分别为96.24%(128/133)、61.65%(82/133),128例行内镜下套扎术序贯治疗技术创新期患者上述指标分别为1.56%(2/128)、3.91%(5/128),2期患者胃潴留、腹泻发生率比较,差异均有统计学意义(x2=233.876,97.883,P<0.05)。
    结论:腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症安全、可行,术中保留迷走神经可降低术后并发症发生率。

     

    Abstract: Objective:To investigate the clinical efficacy of laparoscopic splenectomy combined with pericardial devascularization in the treatment of cirrhotic patients with cirrhotic portal hypertension.
    Methods:The retrospective and descriptive study was conducted. The clinicopathological data of 425 patients with cirrhotic portal hypertension who were admitted to Northern Jiangsu People′s Hospital Affiliated to Yangzhou University were collected. There were 289 males and 136 females, aged (53±11)years, with a range from 21 to 79 years. All the patients were allocated into 3 periods according to the operation time, including 100 patients of early period from February 2012 to March 2014, 156 patients of mature technology period from April 2014 to August 2016, and 169 patients of technology innovation period from september 2016 to December 2018. The patients of early period and mature technology period underwent laparoscopic splenectomy combined with pericardial devascularization, and the patients of technology innovation period underwent vagus nerve-preserving laparoscopic splenectomy combined with pericardial devascularization. Observation indicators: (1) surgical situations; (2) postoperative situations; (3) followup. Patients were followed up by outpatient examination to detect the upper digestive rebleeding, gastric retention, and diarrhea up to March 2019. Sequential therapy of endoscopic variceal ligation (EVL) was slectively performed on patients based on results of gastroscopy. Measurement data with normal distribution were represented as Mean±SD, and comparison between groups was analyzed using ANOVA, and paired comparison was analyzed using the t test. Measurement data with skewed distribution were represented as M (range), and comparison between groups was anlyzed using the KruskalWallis rank sum test, and paired comparison was analyzed using the rank sum test. Count data were described as absolute numbers or percentages, and comparison between groups was analyzed using the chi-square test and Fisher exact probability.
    Results:(1) Surgical situations: the operation time, volume of intraoperative blood loss, cases with intraoperative blood transfusion, cases with conversion to open surgery, and cases with emergency operation for bleeding were (187±46)minutes, 150 mL (range, 50- 1 300 mL), 2, 2 , 1 for patients of early period, (164±22)minutes, 50 mL (range, 30-100 mL), 1, 1, 1 for patients of mature technology period, and (150±18)minutes, 50 mL (range, 10-300 mL), 0 , 0 , 0 for patients of technology innovation period, respectively. There were significant differences in the operation time and volume of intraoperative blood loss between the three groups (F=55.482, x2=94.620, P<0.05). There was no significant difference in the cases with intraoperative blood transfusion, cases with conversion to open surgery, or cases with emergency operation between the three groups (P>0.05). (2) Postoperative situations: 425 patients had oral aspirin enteric-coated tablets for prevention of thrombus, with no perioperative death. Duration of postoperative hospital stay, cases with portal vein thrombosis at postoperative 7 days, cases with pancreatic fistula, cases with pulmonary infection, and cases with abdominal infection were (11.0±2.9)days, 46, 2, 1, 0 for patients of early period, (9.9±1.7)days, 81, 3, 0, 0 for patients of mature technology period, and (8.8±1.3)days, 83, 2, 1, 1 for patients of technology innovation period, respectively. There was a significant difference in the duration of postoperative hospital stay between the three groups (F=39.836, P<0.05), between patients of mature technology and patients of early period (t=3.329, P<0.05), between patients of mature technology period and patients of technology innovation (t=6.502, P<0.05). There was no significant difference in the cases with portal vein thrombosis at postoperative 7 days between the three groups (x2=0.865, P>0.05) and no significant difference in the cases with pancreatic fistula, cases with pulmonary infection, or cases with abdominal infection between the three groups (P>0.05). Patients with portal vein thrombosis at postoperative 7 days had oral aspirin enteric-coated tablets or warfarin for treatment. Patients with pancreatic fistula, pulmonary infection, and abdominal infection were cured and discharged after conservative treatment. (3) Followup: all the 425 patients were followed up for 1-72 months, with a median followup of 36 months. Of the 425 patients, 261 underwent postoperative sequential therapy of EVL, including 133 patients of mature technology period and 128 patients of technology innovation period. The incidence rate of upper digestive rebleeding was 3.83%(10/261) of the 261 patients undergoing postoperative sequential therapy of EVL and 17.68%(29/164) of 164 patients without postoperative sequential therapy of EVL, showing a significant difference between them (x2=23.185, P<0.05). The incidence rates of gastric retention and diarrhea were 96.24%(128/133) and 61.65%(82/133) for 133 patients undergoing sequential therapy of EVL in mature technology period, and 1.56%(2/128) and 3.91% (5/128) for 128 patients undergoing sequential therapy of EVL in technology innovation period, showing significant differences between them (x2=233.876, 97.883, P<0.05).
    Conclusions:It is safe and feasible of laparoscopic splenectomy combined with pericardial devascularization for patients with cirrhotic portal hypertension, and intraoperative vagus nerve-preserving can reduce volume of intraoperative blood loss and incidence of postoperative complications.

     

/

返回文章
返回